PALVELLA THERAPEUTICS, INC

NASDAQ: PVLA (Palvella Therapeutics, Inc.)

Kemas kini terakhir: 06 Oct, 4:58PM

67.95

2.17 (3.30%)

  • 1H 3.30%
  • 5H -32.04%
  • 1B -12.69%
  • 6B 155.16%
  • Tahun Ke Tarikh 466.25%
  • 1T 310.08%
  • 5T -69.00%
Penutupan Terdahulu 65.78
Buka 66.13
Jumlah Dagangan 178,892
Purata Dagangan (3B) 160,015
Modal Pasaran 751,504,192
Harga / Buku (P/B) 31.45
Julat 52 Minggu
11.17 (-83%) — 68.22 (0%)
Tarikh Pendapatan 13 Nov 2025
EPS Cair (TTM) -2.08
Jumlah Hutang/Ekuiti (D/E MRQ) 23.67%
Nisbah Semasa (MRQ) 8.84
Aliran Tunai Operasi (OCF TTM) -16.51 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -5.43 M
Pulangan Atas Aset (ROA TTM) -18.40%
Pulangan Atas Ekuiti (ROE TTM) -89.30%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Palvella Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

1.3
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 4.0
Purata 1.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PVLA 752 M - - 31.45
LEGN 5 B - - 5.06
MAZE 2 B - - 4.82
DNTH 2 B - - 3.45
ELVN 1 B - - 2.56
JBIO 570 M - - -

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 22.87%
% Dimiliki oleh Institusi 47.68%

Pemilikan

Nama Tarikh Syer Dipegang
Clio Asset Management Llc 30 Jun 2025 91,508
Julat 52 Minggu
11.17 (-83%) — 68.22 (0%)
Julat Harga Sasaran
85.00 (25%) — 200.00 (194%)
Tinggi 200.00 (Clear Street, 194.33%) Beli
200.00 (Cantor Fitzgerald, 194.33%) Beli
Median 146.50 (115.60%)
Rendah 85.00 (Oppenheimer, 25.09%) Beli
Purata 147.08 (116.45%)
Jumlah 12 Beli
Harga Purata @ Panggilan 83.65
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BTIG 05 Dec 2025 167.00 (145.77%) Beli 91.65
Clear Street 05 Dec 2025 200.00 (194.33%) Beli 91.65
Craig-Hallum 04 Dec 2025 175.00 (157.54%) Beli 91.65
Stifel 24 Nov 2025 145.00 (113.39%) Beli 98.03
24 Sep 2025 80.00 (17.73%) Beli 58.87
Raymond James 19 Nov 2025 143.00 (110.45%) Beli 96.91
Canaccord Genuity 13 Nov 2025 148.00 (117.81%) Beli 80.50
09 Oct 2025 90.00 (32.45%) Beli 70.09
Chardan Capital 13 Nov 2025 110.00 (61.88%) Beli 80.50
07 Nov 2025 110.00 (61.88%) Beli 77.83
Truist Securities 10 Nov 2025 105.00 (54.53%) Beli 80.29
02 Oct 2025 80.00 (17.73%) Beli 62.63
Cantor Fitzgerald 06 Nov 2025 200.00 (194.33%) Beli 78.63
HC Wainwright & Co. 06 Nov 2025 190.00 (179.62%) Beli 78.63
25 Sep 2025 95.00 (39.81%) Beli 57.69
TD Cowen 06 Nov 2025 97.00 (42.75%) Beli 78.63
Oppenheimer 09 Sep 2025 85.00 (25.09%) Beli 56.71
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
11 Nov 2025 Pengumuman Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06 Nov 2025 Pengumuman Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
05 Nov 2025 Pengumuman Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
04 Nov 2025 Pengumuman Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
13 Oct 2025 Pengumuman U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
24 Sep 2025 Pengumuman Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
17 Sep 2025 Pengumuman Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
15 Sep 2025 Pengumuman Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda